Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mike Ward
Seventure Partners’ Eric de la Fortelle explains how the venture capitalist’s €160bn fund will prosper from the increased understanding of human and microbe interactions.
vitalityDNA is taking the preventative approach to health care with its personalized health and lifestyle plan offering. The start-up will initially target consumers and then health care companies.
Erik Kinnman, CEO of NeuroVive Pharmaceutical, spoke to Scrip about the company's work in mitochondrial medicine. The company aims to develop orphan drugs to treat rare genetic conditions and seek partners for its NASH and liver cancer projects.
By harvesting Lactobacillus reuteri from lactating mothers, Infant Bacterial Therapeutics has developed an approach to treat necrotizing enterocolitis, a major killer of premature babies.
With the Latin American vaccines market forecast to more than quadruple in size from just over $150m to 2015 to just under $700m in 2020, opportunities abound for both homegrown businesses and multinationals looking to tap into local markets.
With the Chinese market growing at 10-15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains how Chinese capital is accessing Western innovation to build a PRC pharma industry.